Actively Recruiting
Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye
Led by Universiti Sains Malaysia · Updated on 2026-02-09
60
Participants Needed
4
Research Sites
23 weeks
Total Duration
On this page
Sponsors
U
Universiti Sains Malaysia
Lead Sponsor
H
Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.
CONDITIONS
Official Title
Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Juvenile open-angle glaucoma patients aged 15 to 40 years at diagnosis
- Compliant with conventional treatment
- Achieved target intraocular pressure
You will not qualify if you...
- Allergy to honey or honey-based products
- OCT signal less than 6/10
- Concurrent retinal diseases or other optic neuropathies
- Systemic neurodegenerative diseases
- Systemic comorbidities such as diabetes mellitus and autoimmune diseases
- Use of other honey-based products in the last 3 months
- Consumption of honey-based products during the 3-month study
- Use of antioxidants, traditional medicines, or herbal products in the last 3 months
- Use of topical steroids, systemic steroids, or non-steroidal anti-inflammatory drugs
- Presence of sepsis
- Compliance less than 75%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Hospital Raja Perempuan Zainab II
Kota Bharu, Kelantan, Malaysia, 15586
Actively Recruiting
2
Hospital Sultan Ismail Petra
Kuala Krai, Kelantan, Malaysia, 18000
Actively Recruiting
3
Hospital Universiti Sains Malaysia
Kubang Kerian, Kelantan, Malaysia, 16150
Actively Recruiting
4
Hospital Sultanah Nur Zahirah
Kuala Terengganu, Terengganu, Malaysia, 20400
Actively Recruiting
Research Team
T
Thamarai Munirathinam, MD(Prague)
CONTACT
A
Azhany Yaakub, MD, MMed, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here